NCT00574132 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers

CSR Summary Not Available
NCT00574132
Primary Citation
Data Specification Not Available

Trial Information

Generic NameBapineuzumabProduct NameTherapeutic AreaBehaviors and Mental DisordersEnrollment1331% Female52.8%% White95.1%

Product ClassMonoclonal AntibodySponsor Protocol NumberELN115727-301Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)72.8

Supporting Documentation

Collected Datasets Available
Protocol with Amendments Available
Statistical Analysis Plan Available
Clinical Study Report Available

Approved Data Requests Associated with this Trial

2023-5218 : ARIA detection, predictability, and relationship to treatment response
2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
2022-5036 : Proof-of-Concept study of a patient selection algorithm for disease modifying treatments in Alzheimer?s disease
2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
2021-4567 : Optimizing Trial design to Achieve Personalized prevention of Alzheimer?s disease
2020-4548 : Getting new insight out of failed AD trials
2020-4448 : Reanalysis of Alzheimer?s Disease Clinical Trials Using Longitudinal Latent Trait Models
2020-4323 : Identification of biomarkers associated with Alzheimer?s disease progression that correlate with responses to medications.
2020-4275 : Machine Learning Applications for Improving the Efficiency of Clinical Trials in Alzheimer's Disease

You are not logged in.

Trial Information

Supporting Documentation

Approved Data Requests Associated with this Trial